Zerhouni trumpets new R&D mindset at Sanofi

Sanofi ($SNY) has reorganized its research and development over the past couple of years, and R&D chief Elias Zerhouni offered up some insights about the new mindset at the French drug giant. For example, the company has emphasized a focus on results of clinical programs over the scientific bureaucracy that has been implicated in the industry's lack of R&D productivity. "The project is what matters, not people's titles," Zerhouni said, as quoted by Bloomberg. "The least hierarchical the model is, the better." Article